ABBV vs. VRTX

Last updated Apr 4, 2026

Compare and contrast key facts about AbbVie Inc. (ABBV) and Vertex Pharmaceuticals Incorporated (VRTX).

Performance

ABBV vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AbbVie Inc. (ABBV) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

ABBV vs. VRTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ABBV AbbVie Inc.	-7.86%	33.08%	18.86%	-0.23%	24.01%	32.43%	27.72%	1.47%	-0.96%	60.07%
VRTX Vertex Pharmaceuticals Incorporated	-3.23%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%

Fundamentals

Market Cap ABBV : $370.48B VRTX : $112.35B
EPS ABBV : $2.38 VRTX : $15.35
PE Ratio ABBV : 87.60 VRTX : 28.58
PS Ratio ABBV : 6.05 VRTX : 9.41
Total Revenue (TTM) ABBV : $61.16B VRTX : $12.00B
Gross Profit (TTM) ABBV : $44.85B VRTX : $10.35B
EBITDA (TTM) ABBV : $28.29B VRTX : $4.74B

Returns By Period

In the year-to-date period, ABBV achieves a -7.86% return, which is significantly lower than VRTX's -3.23% return. Both investments have delivered pretty close results over the past 10 years, with ABBV having a 18.22% annualized return and VRTX not far behind at 18.13%.

ABBV

• 1D: -2.86%
• 1M: -11.58%
• YTD: -7.86%
• 6M: -9.35%
• 1Y: 7.05%
• 3Y*: 13.21%
• 5Y*: 18.43%
• 10Y*: 18.22%

VRTX

• 1D: -1.91%
• 1M: -8.20%
• YTD: -3.23%
• 6M: 8.78%
• 1Y: -9.36%
• 3Y*: 11.52%
• 5Y*: 15.54%
• 10Y*: 18.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ABBV vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABBV

ABBV Risk / Return Rank: 44
ABBV Sharpe Ratio Rank: 47
ABBV Sortino Ratio Rank: 39
ABBV Omega Ratio Rank: 39
ABBV Calmar Ratio Rank: 46
ABBV Martin Ratio Rank: 46

VRTX

VRTX Risk / Return Rank: 27
VRTX Sharpe Ratio Rank: 28
VRTX Sortino Ratio Rank: 26
VRTX Omega Ratio Rank: 26
VRTX Calmar Ratio Rank: 28
VRTX Martin Ratio Rank: 28

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABBV vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AbbVie Inc. (ABBV) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ABBV	VRTX	Difference
Sharpe ratio Return per unit of total volatility	0.19	-0.26	+0.45
Sortino ratio Return per unit of downside risk	0.44	-0.11	+0.54
Omega ratio Gain probability vs. loss probability	1.06	0.98	+0.08
Calmar ratio Return relative to maximum drawdown	0.28	-0.34	+0.62
Martin ratio Return relative to average drawdown	0.62	-0.66	+1.28
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ABBV vs. VRTX - Sharpe Ratio Comparison

The current ABBV Sharpe Ratio is 0.19, which is higher than the VRTX Sharpe Ratio of -0.26. The chart below compares the historical Sharpe Ratios of ABBV and VRTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ABBV	VRTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.19	-0.26	+0.45
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.82	0.54	+0.27
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.71	0.55	+0.16
Sharpe Ratio (All Time) Calculated using the full available price history	0.72	0.26	+0.47

Correlation

The correlation between ABBV and VRTX is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ABBV vs. VRTX - Dividend Comparison

ABBV's dividend yield for the trailing twelve months is around 3.18%, while VRTX has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ABBV AbbVie Inc.	3.18%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%
VRTX Vertex Pharmaceuticals Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

ABBV vs. VRTX - Drawdown Comparison

The maximum ABBV drawdown since its inception was -45.09%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for ABBV and VRTX.

Drawdown Indicators

	ABBV	VRTX	Difference
Max Drawdown Largest peak-to-trough decline	-45.09%	-91.77%	+46.68%
Max Drawdown (1Y) Largest decline over 1 year	-14.86%	-28.06%	+13.20%
Max Drawdown (5Y) Largest decline over 5 years	-21.92%	-29.07%	+7.15%
Max Drawdown (10Y) Largest decline over 10 years	-45.09%	-41.60%	-3.49%
Current Drawdown Current decline from peak	-13.23%	-15.10%	+1.87%
Average Drawdown Average peak-to-trough decline	-10.70%	-37.81%	+27.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.44%	14.38%	-6.94%

Volatility

ABBV vs. VRTX - Volatility Comparison

The current volatility for AbbVie Inc. (ABBV) is 7.85%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 11.81%. This indicates that ABBV experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ABBV	VRTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.85%	11.81%	-3.96%
Volatility (6M) Calculated over the trailing 6-month period	18.09%	21.52%	-3.43%
Volatility (1Y) Calculated over the trailing 1-year period	27.18%	35.84%	-8.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.65%	28.77%	-6.12%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.71%	33.24%	-7.53%

Financials

ABBV vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between AbbVie Inc. and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.72B and revenue of 3.19B. Therefore, the gross margin over that period was 85.4%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.26B and revenue of 3.19B, resulting in an operating margin of 39.6%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.19B and revenue of 3.19B, resulting in a net margin of 37.3%.